Cargando…
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275793/ https://www.ncbi.nlm.nih.gov/pubmed/35856060 http://dx.doi.org/10.1016/S2665-9913(22)00190-4 |
| _version_ | 1784745566652071936 |
|---|---|
| author | Saxena, Amit Engel, Alexis J Banbury, Brittany Hasan, Ghadeer Fraser, Nicola Zaminski, Devyn Masson, Mala Haberman, Rebecca H Scher, Jose U Ho, Gary Law, Jammie Rackoff, Paula Tseng, Chung-E Belmont, H Michael Clancy, Robert M Buyon, Jill P Izmirly, Peter M |
| author_facet | Saxena, Amit Engel, Alexis J Banbury, Brittany Hasan, Ghadeer Fraser, Nicola Zaminski, Devyn Masson, Mala Haberman, Rebecca H Scher, Jose U Ho, Gary Law, Jammie Rackoff, Paula Tseng, Chung-E Belmont, H Michael Clancy, Robert M Buyon, Jill P Izmirly, Peter M |
| author_sort | Saxena, Amit |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9275793 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92757932022-07-14 Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City Saxena, Amit Engel, Alexis J Banbury, Brittany Hasan, Ghadeer Fraser, Nicola Zaminski, Devyn Masson, Mala Haberman, Rebecca H Scher, Jose U Ho, Gary Law, Jammie Rackoff, Paula Tseng, Chung-E Belmont, H Michael Clancy, Robert M Buyon, Jill P Izmirly, Peter M Lancet Rheumatol Comment Elsevier Ltd. 2022-09 2022-07-12 /pmc/articles/PMC9275793/ /pubmed/35856060 http://dx.doi.org/10.1016/S2665-9913(22)00190-4 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Saxena, Amit Engel, Alexis J Banbury, Brittany Hasan, Ghadeer Fraser, Nicola Zaminski, Devyn Masson, Mala Haberman, Rebecca H Scher, Jose U Ho, Gary Law, Jammie Rackoff, Paula Tseng, Chung-E Belmont, H Michael Clancy, Robert M Buyon, Jill P Izmirly, Peter M Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title | Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title_full | Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title_fullStr | Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title_full_unstemmed | Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title_short | Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City |
| title_sort | breakthrough sars-cov-2 infections, morbidity, and seroreactivity following initial covid-19 vaccination series and additional dose in patients with sle in new york city |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275793/ https://www.ncbi.nlm.nih.gov/pubmed/35856060 http://dx.doi.org/10.1016/S2665-9913(22)00190-4 |
| work_keys_str_mv | AT saxenaamit breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT engelalexisj breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT banburybrittany breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT hasanghadeer breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT frasernicola breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT zaminskidevyn breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT massonmala breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT habermanrebeccah breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT scherjoseu breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT hogary breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT lawjammie breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT rackoffpaula breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT tsengchunge breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT belmonthmichael breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT clancyrobertm breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT buyonjillp breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity AT izmirlypeterm breakthroughsarscov2infectionsmorbidityandseroreactivityfollowinginitialcovid19vaccinationseriesandadditionaldoseinpatientswithsleinnewyorkcity |